ENDRA Life Sciences- Warrants (12/05/2022) Operating Income

The latest operating income for NDRAW is $0 as of March 2026. That compares with $2.7M in the prior-year period — down 100.0% year over year. Investors often review this figure alongside ENDRA Life Sciences- Warrants (12/05/2022)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, NDRAW's operating income moved from $2.7M to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ENDRA Life Sciences- Warrants (12/05/2022)'s operating scale or balance-sheet position.

A operating income figure of $0 for NDRAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NDRAW's operating income ($0), review year-over-year change from $2.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack ENDRA Life Sciences- Warrants (12/05/2022)'s operating income against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.